OncoMed Pharmaceuticals’ demcizumab (anti-DLL4, OMP-21M18) has failed to meet its primary endpoint in the Phase 2 YOSEMITE clinical trial in combination with Abraxane (paclitaxel protein-bound particles for injectable suspension) (albumin bound) plus gemcitabine in previously untreated metastatic pancreatic cancer patients.
Medivir has reported positive data from its phase II clinical trial of the topical, skin-directed histone deacetylase (HDAC) inhibitor, remetinostat, in early stage Cutaneous T-cell Lymphoma patients.
Ultragenyx Pharmaceutical and Kyowa Kirin International (KKI), a subsidiary of Kyowa Hakko Kirin (Kyowa Hakko Kirin), have reported positive 64-week data from a pediatric Phase 2 study of burosumab (KRN23) for X-linked hypophosphatemia (XLH) treatment in children aged between five and 12 years.
Allergan announced to advance its wrinkle treatment Botox to third phase after its phase II study showed a partial benefit in treating patients with major depressive disorder (MDD).
Verona Pharma has enrolled and dosed the first patient in a Phase 2a clinical study to evaluate RPL554, as a treatment option for cystic fibrosis (CF).
Amgen and UCB have released results from the fourth year of a Phase 2 study demonstrating the safety and efficacy of a second course of treatment with evenity (romosozumab), an investigational candidate for postmenopausal women with osteoporosis.
Ritter Pharmaceuticals' lactose intolerance treatment, RP-G28, demonstrated efficacy and clinically meaningful benefit in phase 2b/3 clinical trial.
Summit Therapeutics has announced that, subject to regulatory approval, it will go ahead with the planned extension phase of PhaseOut DMD, a Phase 2 clinical trial studying the utrophin modulator ezutromid.
Akashi Therapeutics has secured approval from the US Food and Drug Administration (FDA) to resume clinical development of HT-100 (delayed-release halofuginone) in patients with any of the genetic mutations that cause Duchenne muscular dystrophy (DMD).
A phase 3 study of Lilly’s breast cancer drug, abemaciclib, in combination with fulvestrant, has met its primary endpoint of progression-free survival (PFS).
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.